FDA's Yasmin and Yaz Blood Clots Warning is a Victory for Consumers, says Hissey Kientz, LLP

Share Article

The Food and Drug Administration’s decision to strengthen warnings about the risk of blood clots from using Yaz and Yasmin is a victory for consumers, says the law firm of Hissey Kientz, LLP. On April 10, 2012, the FDA announced that it would add stronger warning labels to Yaz, Yasmin and similar birth control pills about the risk of blood clots these drugs can cause.

If you were injured after taking Yaz, Yasmin or other birth control pills, contact Hissey Kientz, LLP toll-free at 1-866-275-4454, or by email at info@hkllp.com.

The Food and Drug Administration’s decision to strengthen warnings about the risk of blood clots from using Yaz and Yasmin is a victory for consumers, says the law firm of Hissey Kientz, LLP. On April 10, 2012, the FDA announced that it would add stronger warning labels to Yaz, Yasmin and similar birth control pills about the risk of blood clots these drugs can cause.

Yaz and Yasmin contain a type of hormone known as drospirenone (DRSP), which is also found in the drugs Beyaz, Ocella and Loryna. Studies have found that patients taking birth control pills containing DRSP may be up to three times more likely to develop blood clots than users of another birth control brand.

“Evidence has been mounting for years that birth control pills containing drospirenone such as Yaz and Yasmin increase a woman’s risk of blood clots,” says attorney Kathleen McGinn of Hissey Kientz, LLP. “The FDA’s decision to add strong blood clot warnings to these drugs confirms suspicions about the dangers of Yaz and Yasmin compared to other birth control pills.”

The FDA’s warning about Yaz and Yasmin follows the recommendation of an advisory committee, which met in December 2011 to assess the health risks of birth control pills containing DRSP. Based on studies of the blood clot risks of these drugs, the committee voted to recommend stronger warning labels for DRSP birth control pills, including Yaz and Yasmin. This increased blood clot risk could place Yaz and Yasmin users in danger of other serious side effects, including deep vein thrombosis (DVTs), pulmonary embolism (PE), stroke or heart attack.

In 2009, Bayer Pharmaceuticals, the manufacturer of Yaz and Yasmin, was forced to run a $20 million ad campaign after the FDA accused the company of airing a misleading series of television commercials for Yaz. The agency cited Bayer for promoting Yaz for conditions it was not approved by the FDA to treat and for downplaying the risk of side effects associated with the drug.

More than 10,000 Yasmin and Yaz lawsuits have been filed on behalf of patients who suffered blood clots or other injuries after using the birth control pills. At least four class action lawsuits have also been filed on behalf of Yaz or Yasmin users in the U.S. and Canada. Although settlements have been reached in some of these cases, patients who were injured after taking Yaz or Yasmin may still be eligible to file a lawsuit.

If you or a loved one used Yaz, Yasmin or other birth control pills containing DRSP and suffered blood clot-related injuries, you may be eligible to file a lawsuit. To find out if you qualify, contact the lawyers at Hissey Kientz, LLP by calling us toll-free at 1-866-275-4454, or by email at info(at)hkllp(dot)com.

For more information about the side effects of Yaz and Yasmin, visit our online information resource at: http://www.yasminyazsideeffectslawyers.com/.

About Hissey Kientz, LLP
Hissey Kientz, LLP (http://www.hkllp.com) represents individuals who developed blood clots after using Yaz or Yasmin, as well as victims of mesothelioma and other asbestos-related diseases, birth defects linked to antidepressants such as Paxil and Zoloft, DePuy ASR and Pinnacle hip replacements, Actos bladder cancer, problems with transvaginal surgical mesh, Depakote birth defects, the side effects of Crestor, birth defects caused by Topamax, sexual side effects of Propecia and other defective drugs and medical devices.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Craig Whitney
Hissey Kientz, LLP
(512) 320-9100
Email >
Visit website